文献速递前列腺癌

前列腺虚拟高剂量率近距离放疗推量:PROMETHEUS前瞻性多中心试验的5年结果

Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial.
PubMed 文献 · Eur Urol Oncol · 2024-02-01

PROMETHEUS多中心单臂2期试验评估虚拟高剂量率近距离放疗推量(vHDRB)联用常规分割外照射放疗(EBRT)治疗中危或精选高危前列腺癌的安全性和有效性。2014年3月至2018年12月共入组151例患者,中位随访60个月,5年生化/临床无复发生存率为94.1%(95%CI 90-98%),局部控制率为98.7%,晚期≥2级胃肠道和泌尿生殖道毒性发生率分别为1.7%和3.3%。作者结论认为该方案在多中心环境下可行,肿瘤控制率高且毒性低。

要点

  • 5年生化/临床无复发生存率为94.1%(95%CI 90-98%),局部控制率为98.7%。
  • 晚期≥2级胃肠道毒性发生率为1.7%(95%CI 0.3-6.5%),晚期≥2级泌尿生殖道毒性发生率为3.3%(95%CI 1.1-8.8%)。
  • 性功能和尿失禁领域生活质量较基线至60个月轻度下降,肠道领域稳定,排尿梗阻和激素领域改善。

核心结论

  • 基于机架的vHDRB后接常规分割EBRT在多中心环境下可行,5年bcRFR高且毒性低。
  • 该方案正在TROG 18.01 NINJA随机试验中与前列腺超低分割放疗进行比较。

研究设计与样本

  • 多中心、单臂、2期PROMETHEUS试验(ACTRN12615000223538),纳入中危或精选高危前列腺癌患者。
  • 2014年3月至2018年12月共治疗151例患者(74%中危,26%高危),中位年龄69岁,涉及五个中心。
  • vHDRB给予19-20 Gy分两次,间隔1周,随后行常规分割EBRT 46 Gy分23次或36 Gy分12次。
  • 主要终点为生化/临床无复发生存率(bcRFR);毒性采用CTCAE v4分级,生活质量采用EPIC-26问卷收集。

主要发现

  • 中位随访60个月,5年bcRFR为94.1%(95%CI 90-98%),局部控制率为98.7%。
  • 急性2级胃肠道毒性和泌尿生殖道毒性分别发生于6.6%和23.2%的患者,无急性3级毒性。
  • 治疗后60个月,晚期≥2级胃肠道毒性患病率为1.7%(95%CI 0.3-6.5%),晚期≥2级泌尿生殖道毒性患病率为3.3%(95%CI 1.1-8.8%)。
  • 基线至60个月,生活质量在排尿梗阻和激素领域改善,肠道领域稳定,性功能和尿失禁领域轻度下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Despite the high efficacy of high-dose-rate brachytherapy boost (HDRB) in the management of prostate cancer (PC), use of this approach is declining. Similar dosimetry can be achieved using stereotactic body radiotherapy or "virtual HDRB" (vHDRB). The aim of the multicentre, single-arm, phase 2 PROMETHEUS trial (ACTRN12615000223538) was to evaluate the safety and efficacy of vHDRB in patients with PC. METHODS: Patients with intermediate-risk PC or selected patients with high-risk PC were eligible for inclusion. vHDRB was given as 19-20 Gy in two fractions, delivered 1 wk apart, followed by conventionally fractionated external beam radiotherapy (EBRT) at 46 Gy in 23 fractions or 36 Gy in 12 fractions. The primary endpoint was the biochemical/clinical relapse-free rate (bcRFR). Toxicity was graded using Common Terminology Criteria for Adverse Events version 4 and quality of life (QoL) data were collected used the Expanded Prostate Cancer Index Composite-26 questionnaire. KEY FINDINGS AND LIMITATIONS: From March 2014 to December 2018, 151 patients (74% intermediate risk, 26% high risk) with a median age of 69 yr were treated across five centres. Median follow-up was 60 mo. The 5-yr bcRFR was 94.1% (95% confidence interval [CI] 90-98%) and the local control rate was 98.7%. Acute grade 2 gastrointestinal (GI) and genitourinary (GU) toxicity occurred in 6.6% and 23.2% of patients, respectively, with no acute grade 3 toxicity. At 60 mo after treatment, the prevalence of late grade ≥2 GI toxicity was 1.7% (95% CI 0.3-6.5%) and the prevalence of late grade ≥2 GU toxicity was 3.3% (95% CI 1.1-8.8%). Between baseline and 60 mo, QoL improved for urinary obstructive and hormonal domains, was stable for the bowel domain, and deteriorated slightly for the sexual and urinary incontinence domains. CONCLUSIONS: Delivery of gantry-based vHDRB followed by conventionally fractionated EBRT is feasible in a multicentre setting, with high 5-yr bcRFR and low toxicity. This approach is being compared with prostate ultrahypofractionated radiotherapy in the TROG 18.01 NINJA randomised trial (ACTRN12618001806257). PATIENT SUMMARY: The PROMETHEUS trial investigated noninvasive high-dose precision radiotherapy combined with conventional radiotherapy in patients with prostate cancer. We found that this new technique was well tolerated and resulted in better cancer control outcomes than historically reported.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wegener E, Sidhom M, Pryor D, et al. Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial. Eur Urol Oncol. 2024. PMID: 38302321. doi:10.1016/j.euo.2024.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。